A Global Player in Vision Care
Founded in 1949 and headquartered in Worthing on England’s southern coast, Rayner has built a reputation as a leading manufacturer of intraocular lenses and ophthalmic products. Its devices are primarily used in cataract and refractive surgeries — procedures that restore sight and, in many cases, independence.
Beyond lenses, Rayner produces surgical instruments, equipment and eye-care products. The company markets its offerings in more than 80 countries across six continents, supported by direct sales teams operating in 16 nations.
The investment effectively pairs GBL’s capital strength with Rayner’s specialized expertise in a segment poised for steady demand as global populations age.
Advisers on Both Sides
GBL is being advised by Kirkland & Ellis LLP and McDermott Will & Schulte. The Kirkland team is led by partners Vincent Bergin, Adrian Maguire and Carmella Crinnion, while Sharon Lamb serves as lead partner for McDermott. Financial advice to GBL is being provided by EY and Bain & Co.
CVC Capital Partners is represented by Latham & Watkins LLP, with PwC and Boston Consulting Group acting as its financial advisers.
CVC, which first invested in Rayner in 2021, said it intends to remain the lead investor and collaborate with GBL to build on Rayner’s recent expansion. The private equity firm noted that the company has grown significantly during the initial phase of CVC’s ownership.
GBL declined to comment beyond its statement. CVC did not immediately respond to a request for further comment.
